ReviewExperimental and therapeutic medicine2025
Advances in the molecular signaling mechanisms of VEGF/VEGFR2 in fundus neovascularization disease (Review).
Review in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The role of the epidermal growth factor receptor (EGFR/ErbB1) in diabetic retinopathy and its therapeutic implications.Journal of translational medicine · 2026Review
- Tyrosine Kinase Receptors, Inhibition, and Potential Role in the Pharmacotherapy of Retinal Disorders.Ophthalmology and therapy · 2026Review
- Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience.Cells · 2026Review
- Article
- Vascular Endothelial Growth Factor/Angiopoietin-2 Bispecific Antibody-Induced Vascular Normalization: From Basic Mechanisms to Therapeutic Applications in Breast Cancer.Immunity, inflammation and disease · 2026Review
- Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration.Frontiers in genetics · 2026Article
- Unveiling Vascular Dynamics: Introducing theBiomedicines · 2025Article
- Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.iScience · 2025Review
- The controversial role of nutraceuticals vs. drugs in proliferative retinopathies.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fundus neovascularization disease is a blinding eye disease, and represents an umbrella term for a group of disorders in which VEGF and its receptor VEGFR2 play important roles in promoting neovascularization. Compared with physiological angiogenesis, pathological angiogenesis involves several different regulatory mechanisms, vascular structures and functions, as well as microenvironmental effects. Although the role of VEGF and its receptor in angiogenesis is well documented, research on its major molecular signaling mechanisms is limited. In the present review, a basic overview of the VEGF and VEGFR2 pathways, including their downstream signaling mechanisms and the latest therapeutic advances in the context of fundus neovascularization disease, is provided, and the limitations and future perspectives of current anti-VEGF therapies are discussed. Overall, the purpose of the current review is to provide information on the molecular signaling mechanisms associated with VEGF and VEGFR2 and to perform an in-depth examination of these molecular signaling pathways and their interaction mechanisms. These interaction mechanisms are expected to facilitate the development of more targeted and long-lasting therapeutic regimens and provide novel concepts for the treatment of fundus neovascularization disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.